HAM
MCID: MYL057
MIFTS: 40

Myelopathy, Htlv-1-Associated (HAM)

Categories: Infectious diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Myelopathy, Htlv-1-Associated

MalaCards integrated aliases for Myelopathy, Htlv-1-Associated:

Name: Myelopathy, Htlv-1-Associated 57 55
Tropical Spastic Paraparesis 59 72
Human T-Lymphotropic Virus Type I-Associated Myelopathy/tropical Spastic Paraparesis 59
Human T-Lymphotropic Virus Type-1-Associated Myelopathy/tropical Spastic Paraparesis 59
Htlv-1-Associated Myelopathy/tropical Spastic Paraparesis 59
Familial Spastic Paraparesis, Htlv-1-Associated 57
Htlv-1 Associated Myelopathy 54
Htlv1-Associated Myelopathy 37
Ham/tsp 59
Ham 57
Tsp 59

Characteristics:

Orphanet epidemiological data:

59
tropical spastic paraparesis
Inheritance: Not applicable; Age of onset: Adult;

OMIM:

57
Inheritance:
possible genetic factors


Classifications:



External Ids:

OMIM 57 159580
KEGG 37 H01724
ICD10 via Orphanet 34 G04.1
UMLS via Orphanet 73 C0030481
Orphanet 59 ORPHA289326
MedGen 42 C0030481
UMLS 72 C0030481

Summaries for Myelopathy, Htlv-1-Associated

NINDS : 54 For several decades the term “tropical spastic paraparesis” (TSP) has been used to describe a chronic and progressive disease of the nervous system that affects adults living in equatorial areas of the world and causes progressive weakness, stiff muscles, muscle spasms, sensory disturbance, and sphincter dysfunction. The cause of TSP was obscure until the mid-1980s, when an important association was established between the human retrovirus — human T-cell lymphotrophic virus type 1 (also known as HTLV-1) — and TSP. TSP is now called HTLV-1 associated myelopathy/ tropical spastic paraparesis or HAM/TSP. The HTLV-1 retrovirus is thought to cause at least 80 percent of the cases of HAM/TSP by impairing the immune system. In addition to neurological symptoms of weakness and muscle stiffness or spasms, in rare cases individuals with HAM/TSP also exhibit uveitis (inflammation of the uveal tract of the eye), arthritis (inflammation of one or more joints), pulmonary lymphocytic alveolitis (inflammation of the lung), polymyositis (an inflammatory muscle disease), keratoconjunctivitis sicca (persistent dryness of the cornea and conjunctiva), and infectious dermatitis (inflammation of the skin). The other serious complication of HTLV-1 infection is the development of adult T-cell leukemia or lymphoma. Nervous system and blood-related complications occur only in a very small proportion of infected individuals, while most remain largely without symptoms throughout their lives. The HTLV-1 virus is transmitted person-to-person via infected cells: breast-feeding by mothers who are seropositive (in other words, have high levels of virus antibodies in their blood), sharing infected needles during intravenous drug use, or having sexual relations with a seropositive partner. Less than 2 percent of HTLV-1 seropositive carriers will become HAM/TSP patients.

MalaCards based summary : Myelopathy, Htlv-1-Associated, also known as tropical spastic paraparesis, is related to htlv-1 associated myelopathy/tropical spastic paraparesis and tropical spastic paraparesis. An important gene associated with Myelopathy, Htlv-1-Associated is CNTN2 (Contactin 2), and among its related pathways/superpathways is Human T-cell leukemia virus 1 infection. The drugs Pentoxifylline and Zidovudine have been mentioned in the context of this disorder. Affiliated tissues include t cells, spinal cord and lung, and related phenotypes are abnormal pyramidal sign and spastic paraparesis

KEGG : 37
Human T lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a chronic progressive myelopathy characterized by bilateral pyramidal tract involvement with sphincteric disturbances. HTLV-1 is the etiologic agent of HAM/TSP. Although the majority of HTLV-1-infected individuals remain asymptomatic during their lifetime, approximately one percent of this population develops a myelopathy consisting of a chronic inflammation of the white and gray matter of the spinal cord. Early in the disease process the leptomeninges, blood vessels and parenchyma are infiltrated with CD4+, CD8+, B lymphocytes and foamy macrophages, whereas later in the disease CD8+ lymphocytes predominate with subsequent progression to a relatively acellular, atrophic pattern with axonal and myelin degeneration.

Wikipedia : 75 Tropical spastic paraparesis (TSP), is a medical condition that causes weakness, muscle spasms, and... more...

More information from OMIM: 159580

Related Diseases for Myelopathy, Htlv-1-Associated

Diseases related to Myelopathy, Htlv-1-Associated via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 304)
# Related Disease Score Top Affiliating Genes
1 htlv-1 associated myelopathy/tropical spastic paraparesis 12.2
2 tropical spastic paraparesis 11.9
3 human t-cell leukemia virus type 1 11.6
4 retrovirus-associated myelopathy 11.5
5 autoimmune polyendocrine syndrome, type i, with or without reversible metaphyseal dysplasia 11.2
6 spastic paraparesis 10.9
7 t-cell leukemia 10.6
8 leukemia, t-cell, chronic 10.6
9 adult t-cell leukemia 10.6
10 papillomatosis, confluent and reticulated 10.6
11 measles 10.4
12 yaws 10.3
13 leukemia, acute myeloid 10.2
14 posttransplant acute limbic encephalitis 10.2
15 myeloid leukemia 10.2
16 spasticity 10.2
17 creutzfeldt-jakob disease 10.2
18 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.2
19 sexual disorder 10.2
20 mumps 10.2
21 lathyrism 10.2
22 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.2
23 t-cell adult acute lymphocytic leukemia 10.2
24 triiodothyronine receptor auxiliary protein 10.2
25 foodborne botulism 10.2
26 listeriosis 10.2
27 neurogenic bladder 10.2
28 neutropenia 10.2
29 staphyloenterotoxemia 10.2
30 depression 10.2
31 major depressive disorder 10.1
32 detrusor sphincter dyssynergia 10.1
33 leukemia 10.1
34 polyneuropathy 10.1
35 mental depression 10.1
36 myelitis 10.1
37 myositis 10.1
38 leukemia, acute lymphoblastic 10.1
39 chops syndrome 10.1
40 lymphocytic leukemia 10.1
41 uveitis 10.1
42 acute cystitis 10.1
43 diarrhea 10.1
44 paraplegia 10.1
45 mite infestation 10.1
46 systemic lupus erythematosus 10.1
47 schistosoma mansoni infection, susceptibility/ 10.1
48 kuru 10.1
49 mycosis fungoides 10.1
50 neurodegeneration with brain iron accumulation 2a 10.1

Graphical network of the top 20 diseases related to Myelopathy, Htlv-1-Associated:



Diseases related to Myelopathy, Htlv-1-Associated

Symptoms & Phenotypes for Myelopathy, Htlv-1-Associated

Human phenotypes related to Myelopathy, Htlv-1-Associated:

32
# Description HPO Frequency HPO Source Accession
1 abnormal pyramidal sign 32 HP:0007256
2 spastic paraparesis 32 HP:0002313
3 myelopathy 32 HP:0002196

Symptoms via clinical synopsis from OMIM:

57
Neuro:
myelopathy
pyramidal signs
tropical spastic paraparesis
mild or no sensory disturbance

Lab:
anti-htlv-i antibodies in both serum and csf

Clinical features from OMIM:

159580

Drugs & Therapeutics for Myelopathy, Htlv-1-Associated

Drugs for Myelopathy, Htlv-1-Associated (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 47)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pentoxifylline Approved, Investigational Phase 3 6493-05-6 4740
2
Zidovudine Approved Phase 2, Phase 3 30516-87-1 35370
3
Lamivudine Approved, Investigational Phase 2, Phase 3 134678-17-4 60825
4
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
5
Mogamulizumab Approved, Investigational Phase 3 1159266-37-1
6 Anti-Infective Agents Phase 2, Phase 3
7 Anti-HIV Agents Phase 2, Phase 3
8 Anti-Retroviral Agents Phase 2, Phase 3
9 Antiviral Agents Phase 2, Phase 3
10 Immunologic Factors Phase 2, Phase 3
11 Free Radical Scavengers Phase 3
12 Antioxidants Phase 3
13 Phosphodiesterase Inhibitors Phase 3
14 Protective Agents Phase 3
15 Radiation-Protective Agents Phase 3
16 Platelet Aggregation Inhibitors Phase 3
17 Vasodilator Agents Phase 3
18 Dermatologic Agents Phase 2, Phase 3
19 Antirheumatic Agents Phase 2, Phase 3
20 Nucleic Acid Synthesis Inhibitors Phase 2, Phase 3
21 Reverse Transcriptase Inhibitors Phase 2, Phase 3
22 Antimetabolites Phase 2, Phase 3
23 Antifungal Agents Phase 2, Phase 3
24 Cyclosporins Phase 2, Phase 3
25 Immunosuppressive Agents Phase 2, Phase 3
26 Calcineurin Inhibitors Phase 2, Phase 3
27
Interferon beta-1a Approved, Investigational Phase 2 145258-61-3 6438354
28
Infliximab Approved Phase 2 170277-31-3
29 Adjuvants, Immunologic Phase 2
30 Interferon-beta Phase 2
31 interferons Phase 2
32 Janus Kinase Inhibitors Phase 2
33 Gastrointestinal Agents Phase 2
34 Antibodies Phase 1
35 Antibodies, Monoclonal Phase 1
36 Immunoglobulins Phase 1
37
Valproic acid Approved, Investigational 99-66-1 3121
38 Raltegravir Potassium Early Phase 1
39 Integrase Inhibitors Early Phase 1
40 HIV Integrase Inhibitors Early Phase 1
41 Neurotransmitter Agents
42 Central Nervous System Depressants
43 Tranquilizing Agents
44 Psychotropic Drugs
45 GABA Agents
46 Anticonvulsants
47 Antimanic Agents

Interventional clinical trials:

(show all 21)
# Name Status NCT ID Phase Drugs
1 Open-Label, Exploratory Study of the Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP) Unknown status NCT01343355 Phase 2, Phase 3 Tamibarotene
2 Effectiveness of Pentoxifylline in Attenuating Neurological Disease Associated With HTLV-1 and Negative Modulator of Pathological Immune Response. Completed NCT01472263 Phase 3 Pentoxifylline;Placebo
3 Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial Completed NCT00272480 Phase 2, Phase 3 Zidovudine/lamivudine;Placebos
4 The HAM Ciclosporin Study : an Observational Trial of Therapy in Early or Progressing HAM/TSP Completed NCT00773292 Phase 2, Phase 3 ciclosporin
5 A Phase 3 Multicenter, Randomized, Double-Blind and Placebo-Controlled Study, and Open Study of KW-0761 in Patients With HTLV-1 Associated Myelopathy (HAM) Active, not recruiting NCT03191526 Phase 3 KW-0761 0.3 mg/kg IV;Placebo (saline)
6 Combined Virological and Immunological Evaluation of Treatment of Patients With Early HTLV-1-Associated Myelopathy With Recombinant Human Interferon Beta-1a Completed NCT00001785 Phase 2 Recombinant human interferon beta-1a
7 Phase II Trial Evaluating the Safety and Efficacy of Ruxolitinib in Patients With Smoldering and Chronic Adult T-cell Leukemia (ATL) Recruiting NCT01712659 Phase 2 Ruxolitinib;ruxolitinib
8 An Open, Non-randomised Pilot Study of Anti-TNF-alpha Therapy in Early or Progressing HAM/TSP Terminated NCT00823641 Phase 2 Infliximab
9 Immunotherapy of Natural Killer in HTLV-1 Associated Myelopathy Unknown status NCT02961712 Phase 1
10 Phase I Study of HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) Using the Humanized MiK-Beta-1 Monoclonal Antibody Directed Toward the IL-2L-15R-Beta; Subunit (CD122) That Blocks IL-15 Action Completed NCT00076843 Phase 1 Hu MiK-Beta-1
11 MRI Investigation Of The CNS In HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) Completed NCT00034723
12 Effects of Physiotherapy in the Treatment of Neurogenic Bladder in Patients Infected With Human T-Lymphotropic Virus 1 Completed NCT01651819
13 Pilot Study of Raltegravir, an Integrase Inhibitor, in Human T-Cell Lymphotrophic Virus-1(HTLV-1) Associated Myelopathy, Tropical Spastic Paraparesis (HAM/TSP) Completed NCT01867320 Early Phase 1 Raltegravir
14 A Study of Familial and Genetic Aspects of Adult T-Cell Leukemia/Lymphoma, Tropical Spastic Paraparesis and Infective Dermatitis in Jamaica Completed NCT00340821
15 NIB Repository Protocol Completed NCT01581567
16 Effect of Raltegravir in Patients With Myelopathy/Tropical Spastic Paraparesis Associated With Infection by Human T-Lymphotropic Virus 1 (HTLV-1). Pilot Study Completed NCT02655471 Early Phase 1 "Raltegravir" and "Zidovudine"
17 Influence of IL28B Genetic Variation on the Phenotype Infection of HTLV-1 Completed NCT01754311
18 Retrovirus Epidemiology Donor Study I (REDS I) Completed NCT00005278
19 Immuno-Virological Evaluation of Human T Cell Lymphotropic Virus Infection and Associated Neurological Diseases Recruiting NCT00001778
20 Electromiography Study in the Respiratory Muscle Training in Human Lymphotropic Virus Type 1 Recruiting NCT03829709
21 Open Label Study of the Clinical and Laboratory Effects of Valproic Acid In HAM/TSP Terminated NCT00519181 Valproic Acid

Search NIH Clinical Center for Myelopathy, Htlv-1-Associated

Genetic Tests for Myelopathy, Htlv-1-Associated

Anatomical Context for Myelopathy, Htlv-1-Associated

MalaCards organs/tissues related to Myelopathy, Htlv-1-Associated:

41
T Cells, Spinal Cord, Lung, Skin, Eye, Breast, Brain

Publications for Myelopathy, Htlv-1-Associated

Articles related to Myelopathy, Htlv-1-Associated:

(show top 50) (show all 1509)
# Title Authors PMID Year
1
Endemic tropical spastic paraparesis associated with human T-lymphotropic virus type I: a clinical and seroepidemiological study of 25 cases. 38 8
3030190 1987
2
HTLV-I and HTLV-III antibodies and tropical spastic paraparesis. 38 8
2866324 1985
3
Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. 38 8
2863442 1985
4
Familial clustering of HTLV-I infection in southeastern Italy. 8
7603241 1995
5
Seminars in medicine of the Beth Israel Hospital, Boston. Pathogenesis of diseases induced by human lymphotropic virus type I infection. 8
8455685 1993
6
Familial spastic paraparesis syndrome associated with HTLV-I infection. 8
2388670 1990
7
Bottle-feeding can prevent transmission of HTLV-I from mothers to their babies. 8
2778340 1989
8
The first report of familial adult T-cell leukemia lymphoma in the United States. 8
2895582 1988
9
Familial occurrence of HTLV-I--associated myelopathy. 8
2894196 1988
10
Familial cases of HTLV-I-associated myelopathy. 8
2892464 1987
11
Intrafamilial clustering of anti-ATLA-positive persons. 8
2876624 1986
12
Intrafamilial transmission of adult T cell leukemia virus. 8
2877031 1986
13
HTLV-I associated myelopathy, a new clinical entity. 8
2871307 1986
14
High frequencies of Th1-type CD4(+) T cells specific to HTLV-1 Env and Tax proteins in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. 9 38
11964301 2002
15
Increased levels of soluble Fas ligand in CSF of rapidly progressive HTLV-1-associated myelopathy/tropical spastic paraparesis patients. 9 38
10430056 1999
16
Predominant expression of Fas ligand mRNA in CD8+ T lymphocytes in patients with HTLV-1 associated myelopathy. 9 38
9817448 1998
17
Conflicting effects of poly(ADP-ribose) polymerase inhibitor on cell-mediated and virion-mediated HTLV-1 infection. 38
31299194 2019
18
Curcumin increased the expression of c-FLIP in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients. 38
31074052 2019
19
Hodgkin-like adult T-cell leukemia/lymphoma that developed during the follow-up of HTLV-1 associated myelopathy/tropical spastic paraparesis. 38
31391405 2019
20
Comparative virology of HTLV-1 and HTLV-2. 38
31391116 2019
21
Human T-Cell Lymphotropic Virus Type 1 and associated diseases in Latin America. 38
31183938 2019
22
Balance Impairments in Patients with Human T-Cell Lymphotropic Virus Type 1 Infection. 38
31391511 2019
23
Clinical trial of a humanized anti-IL-2/IL-15 receptor β chain in HAM/TSP. 38
31402625 2019
24
Current approaches for detection of human T-lymphotropic virus Type 1: A systematic review. 38
30633358 2019
25
Pentosan Polysulfate Demonstrates Anti-human T-Cell Leukemia Virus Type 1 Activities In Vitro and In Vivo. 38
31167921 2019
26
Memory impairment: an intermediate clinical syndrome symptom in HTLV-1-infected patients? 38
31314846 2019
27
Phenotypic and functional changes in gamma delta T lymphocytes from HTLV-1 carriers. 38
31287591 2019
28
Prevalence of human T-cell lymphotropic virus and the socio-demographic and risk factors associated with the infection among post-natal clinics women in Zaria, Nigeria. 38
31339431 2019
29
Low Frequency Of Regulatory B-Cells And Increased CD4+ and CD8+ Interferon-γ-producing cells in patients with tropical spastic paraparesis associated with human T-cell lymphotropic virus type. 38
31340370 2019
30
Repurposing multiple sclerosis drugs: a review of studies in neurological and psychiatric conditions. 38
31100209 2019
31
Essential Role of HTLV-1 orf-I in Lethal Proliferation of CD4+ Cells in Humanized Mice. 38
31315992 2019
32
HTLV-1-infected asymptomatic carriers compared to HAM/TSP patients over-express the apoptosis- and cytotoxicity-related molecules. 38
31317252 2019
33
Delimitation of the upstream region of NFKBIA gene associated with HTLV-1-associated myelopathy/tropical spastic paraparesis using candidate Tag-SNPs in Peruvian HTLV-1 infected individuals. 38
31226330 2019
34
Human T-cell lymphotropic virus 1/2 and human immunodeficiency virus antibodies identification among transactional sex workers and drug users in the Dominican Republic. 38
30892643 2019
35
Functional capacity of natural killer cells in HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients. 38
31101076 2019
36
Thioredoxin reductase gene expression and activity among human T-cell lymphotropic virus type 1-infected patients. 38
30489643 2019
37
Pain and Quality of Life in Human T-cell Lymphotropic Virus Type 1-Associated Myelopathy or Tropical Spastic Paraparesis After Home-Based Exercise Protocol: A Randomized Clinical Trial. 38
31038621 2019
38
Efficacy of mirabegron for overactive bladder with human T cell lymphotropic virus-1 associated myelopathy. 38
29473309 2019
39
Infective dermatitis: A purely cutaneous manifestation of HTLV-1 infection. 38
31010607 2019
40
Seroprevalence of HTLV-1/2 Among Voluntary Blood Donors in Vietnam. 38
30565470 2019
41
Role of Receptors for Advanced Glycation End Products and High-Mobility Group Box 1 in the Outcome of Human T Cell Lymphotropic Type 1 Infection. 38
30585773 2019
42
Revisiting Keratoconjunctivitis sicca associated with Human T-Cell Lymphotropic Virus Type 1: prevalence, clinical aspects and proviral load. 38
31059675 2019
43
Incomplete myelopathy and human T cell lymphotropic virus type-1 (HTLV-1). 38
30291566 2019
44
Robust, atlas-free, automatic segmentation of brain MRI in health and disease. 38
30828660 2019
45
Neuroimmunology of Human T-Lymphotropic Virus Type 1-Associated Myelopathy/Tropical Spastic Paraparesis. 38
31105674 2019
46
Infective dermatitis associated with HTLV-1 infection in a girl from Trinidad: Case report and review of literature. 38
30338553 2019
47
Association Between HTLV-1 Genotypes and Risk of HAM/TSP. 38
31156605 2019
48
Molecular detection of human T-lymphotropic virus type 1 infection among oncology patients in Germany: A retrospective view. 38
31136642 2019
49
The Role of CXCR3 in Neurological Diseases. 38
29119926 2019
50
Molecular targeting for treatment of human T-lymphotropic virus type 1 infection. 38
30551530 2019

Variations for Myelopathy, Htlv-1-Associated

Expression for Myelopathy, Htlv-1-Associated

Search GEO for disease gene expression data for Myelopathy, Htlv-1-Associated.

Pathways for Myelopathy, Htlv-1-Associated

Pathways related to Myelopathy, Htlv-1-Associated according to KEGG:

37
# Name Kegg Source Accession
1 Human T-cell leukemia virus 1 infection hsa05166

GO Terms for Myelopathy, Htlv-1-Associated

Cellular components related to Myelopathy, Htlv-1-Associated according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 8.62 FASLG CNTN2

Sources for Myelopathy, Htlv-1-Associated

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....